Pharmacologic Approach to Management of Clostridium difficile Infection

Crit Care Nurs Q. 2019 Jan/Mar;42(1):2-11. doi: 10.1097/CNQ.0000000000000232.

Abstract

Clostridium difficile is a gram-positive, anaerobic, spore-forming bacterium that is the leading cause of nosocomial infections in hospitals in the United States. Critically ill patients are at high risk for C. difficile infection (CDI) and face potentially detrimental effects, including prolonged hospitalization, risk of recurrent disease, complicated surgery, and death. CDI requires a multidisciplinary approach to decrease hospital transmission and improve treatment outcomes. This article briefly reviews the current literature and guideline recommendations for treatment and prevention of CDI, with a focus on antibiotic treatment considerations including dosing, routes of administration, efficacy data, adverse effects, and monitoring parameters.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Clostridioides difficile / isolation & purification*
  • Clostridioides difficile / pathogenicity
  • Clostridium Infections / diagnosis*
  • Clostridium Infections / drug therapy*
  • Cross Infection / prevention & control
  • Hospitals
  • Humans
  • Probiotics
  • Proton Pump Inhibitors

Substances

  • Anti-Bacterial Agents
  • Proton Pump Inhibitors